Abstract :

Background: Hypertension is a major risk factor for cardiovascular disease and is commonly associated with overweight status. Dietary interventions using functional foods are considered effective non-pharmacological strategies for blood pressure control. Moringa (Moringa oleifera) leaves contain bioactive compounds such as potassium, calcium, magnesium, flavonoids, and antioxidants, which may contribute to blood pressure reduction. However, evidence regarding the effect of Moringa leaf soup on blood pressure among overweight individuals is still limited.

Objective: This study aimed to determine the effect of Moringa leaf soup consumption on changes in blood pressure among overweight employees at Nusa Cendana University.

Methods: This pre-experimental study employed a one-group pretest–posttest design involving 27 overweight employees selected through purposive sampling. Participants consumed 100 grams of Moringa leaf soup daily for seven days. Blood pressure was measured before and after the intervention using a digital sphygmomanometer. Data were analyzed using the Wilcoxon signed-rank test.

Results: A significant reduction in systolic blood pressure was observed after the intervention (p < 0.05). However, no significant change was found in diastolic blood pressure (p > 0.05).

Conclusion: Moringa leaf soup consumption for seven days significantly reduced systolic blood pressure but had no significant effect on diastolic blood pressure. This intervention may serve as a complementary dietary approach for blood pressure management in overweight individuals.

---

Keywords :

Blood pressure, hypertension, Moringa Leaf, Moringa oleifera, overweight

---

References :

1. World Health Organization. Hypertension. Geneva: World Health Organization; 2023.
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019. Lancet. 2021;398(10304):957–80.
3. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.
4. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity. Am J Med Sci. 2008;336(4):284–90.
5. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13–115.
6. Leone A, Spada A, Battezzati A, Schiraldi A, Aristil J, Bertoli S. Cultivation, genetic, ethnopharmacology, phytochemistry and pharmacology of Moringa oleifera leaves: an overview. Int J Mol Sci. 2015;16(6):12791–835.
7. Mbikay M. Therapeutic potential of Moringa oleifera leaves in chronic hyperglycemia and dyslipidemia: a review. Front Pharmacol. 2012;3:24.
8. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Lancet. 2002;359(9311): 1247–53.
9. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117–24.
10. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the DASH diet. N Engl J Med. 2001;344(1):3–10.
11. Grassi G, Seravalle G, Quarti-Trevano F, et al. Excessive sympathetic activation in obesity hypertension. Hypertension. 2007;49(6):1213–8.
12. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48(5):787–96.
13. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin–angiotensin–aldosterone system: role in metabolic syndrome? Int J Biochem Cell Biol. 2003;35(6):807–25.
14. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension. Circulation. 2003;107(22):2864–9.
15. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. Circulation. 1997;96(1):308–15.
16. Laurent S, Boutouyrie P. Arterial stiffness and hypertension in the elderly. Front Cardiovasc Med. 2020;7:544302.
17. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors. BMJ. 2013;346:f1378.
18. He FJ, MacGregor GA. Beneficial effects of potassium on human health. Physiol Plant. 2008;133(4):725–35.
19. Aaron KJ, Sanders PW. Role of dietary salt and potassium intake in cardiovascular health and disease. Hypertension. 2013;61(3):507–13.
20. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27(3):481–90.
21. Morris RC, Sebastian A, Forman A, Tanaka M, Schmidlin O. Normotensive salt sensitivity. Hypertension. 1999;33(1):18–23.
22. Luft FC, Miller JZ, Grim CE, et al. Salt sensitivity and resistance of blood pressure. Hypertension. 1991;17(1 Suppl):I102–8.
23. Resnick LM, Gupta RK, Bhargava KK, et al. Cellular ions in hypertension. Hypertension. 1991;17(6 Pt 2):951–7.
24. Barbagallo M, Dominguez LJ. Magnesium and hypertension. Nutrients. 2010;2(11):1089–106.
25. Touyz RM. Magnesium in clinical medicine. Front Biosci. 2004;9:1278–93.
26. Maier JA. Endothelial cells and magnesium. Int J Mol Sci. 2014;15(7):11747–57.
27. Cunha AR, Umbelino B, Correia ML, Neves MF. Magnesium and vascular changes in hypertension. Int J Hypertens. 2012;2012:754250.
28. Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. Cigarette smoking and hypertension. Curr Pharm Des. 2010;16(23):2518–25.
29. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93(3):621–35.
30. Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 2013;87(7):1157–80.
31. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease. Circulation. 2006;113(13):1708–14.
32. Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bächler JP. Relationship between oxidative stress and essential hypertension. Hypertens Res. 2007;30(12):1159–67.
33. Houston MC. Nutraceuticals, vitamins, antioxidants, and minerals in hypertension. J Clin Hypertens. 2010;12(4):246–59.
34. Safar ME. Arterial stiffness as a risk factor for clinical hypertension. Nat Rev Cardiol. 2018;15(2):97–105.
35. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk. Hypertension. 1999;33(5):1111–7.
36. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension. Hypertension. 2013;61(6):1171–80.
37. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3):625–33.
38. Tilman D, Clark M. Global diets link environmental sustainability and human health. Nature. 2014;515(7528):518–22.
39. Popkin BM. Nutrition transition and the global diabetes epidemic. Curr Diab Rep. 2015;15(9):64.
40. Gupta R, Xavier D. Hypertension: The most important non communicable disease risk factor in India. Indian Heart J. 2018;70(4):565–72.
41. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 5th ed. New York: Springer; 2015.
42. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement. BMJ. 2010;340:c332.
43. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions. BMJ. 2008;337:a1655.
44. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension. Hypertension. 2006;47(2):296–308.
45. Obarzanek E, Proschan MA, Vollmer WM, et al. Individual blood pressure responses to changes in salt intake. Hypertension. 2003;42(4):459–67.
46. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption. N Engl J Med. 2014;371(7):624–34.
47. Guideline: Sodium intake for adults and children. Geneva: World Health Organization; 2012.
48. Chen X, Wei G, Jalili T, et al. Dietary potassium reduces blood pressure. Hypertension. 2008;52(6):1085–92.
49. McDonough AA, Youn JH. Potassium homeostasis. Am J Physiol Renal Physiol. 2017;312(5):F799–F809.
50. Houston MC, Harper KJ. Potassium, magnesium, and calcium. J Clin Hypertens. 2008;10(7 Suppl 2):3–11.
51. Fahey JW. Moringa oleifera: A review of the medical evidence. Trees Life J. 2005;1:5.
52. Gopalakrishnan L, Doriya K, Kumar DS. Moringa oleifera: A review on nutritive importance and its medicinal application. Food Sci Hum Wellness. 2016;5(2):49–56.
53. Vergara-Jimenez M, Almatrafi MM, Fernandez ML. Bioactive components in Moringa oleifera Nutrients. 2017;9(8):870.
54. Olson ME, Fahey JW. Moringa leaf as a functional food. Phytochemistry. 2011;72(5):527–35.
55. Thurber MD, Fahey JW. Adoption of Moringa oleifera. Econ Bot. 2009;63(2):158–71.
56. Kumssa DB, Joy EJM, Young SD, et al. The nutritional value of Moringa oleifera PLoS One. 2017;12(6):e0175506.
57. Hulley SB, Cummings SR, Browner WS, et al. Designing Clinical Research. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
58. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
59. Hernán MA, Robins JM. Causal Inference. Boca Raton: Chapman & Hall/CRC; 2020.
60. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
61. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary fats with mortality. Ann Intern Med. 2014;160(6):398–406.
62. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90.
63. Hu FB. Plant-based foods and prevention of cardiovascular disease. Am J Clin Nutr. 2003;78(3 Suppl):544S–51S.
64. Springmann M, Mason-D’Croz D, Robinson S, et al. Health effects of dietary risks. Lancet. 2016;387(10031):1937–46.
65. Willett W, Rockström J, Loken B, et al. Food in the Anthropocene. Lancet. 2019;393(10170):447–92.
66. Mozaffarian D. Dietary and policy priorities for cardiovascular disease. Circulation. 2016;133(2):187–225.